Thursday, January 28, 2016 5:37:49 AM
Definitely still a need for the product and the product on surface seems well positioned. The company seems to still be in play or position to execute, so what explanation is there? Most plausible is the realization that the complexities/logistics both financially and in production was going to cause significant delay..
The one benefit of low equity valuation is it provides opportunity for key stakeholders in the entire process, and opportunity investment wise can yield key partnerships for the long haul..
Optimistic this could be one if those most impressive penny stocks from this level. Cautious though understanding there is much complexity and uncertain timelines. Worth a small buy and hold. GLTA.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM